BACKGROUND: The best way to offer non-invasive respiratory support across several aetiologies of acute respiratory failure (ARF) is presently unclear. Both high flow nasal catheter (HFNC) therapy and non-invasive positive pressure ventilation (NIPPV) may improve outcomes in critically ill patients by avoiding the need for invasive mechanical ventilation (IMV). OBJECTIVE: Describe the details of the protocol and statistical analysis plan designed to test whether HFNC therapy is non-inferior or even superior to NIPPV in patients with ARF due to different aetiologies. METHODS: RENOVATE is a multicentre adaptive randomised controlled trial that is recruiting patients from adult emergency departments, wards and intensive care units (ICUs). It takes advantage of an adaptive Bayesian framework to assess the effectiveness of HFNC therapy versus NIPPV in four subgroups of ARF (hypoxaemic non-immunocompromised, hypoxaemic immunocompromised, chronic obstructive pulmonary disease exacerbations, and acute cardiogenic pulmonary oedema). The study will report the posterior probabilities of non-inferiority, superiority or futility for the comparison between HFNC therapy and NIPPV. The study assumes neutral priors and the final sample size is not fixed. The final sample size will be determined by a priori determined stopping rules for non-inferiority, superiority and futility for each subgroup or by reaching the maximum of 2000 patients. OUTCOMES: The primary endpoint is endotracheal intubation or death within 7 days. Secondary outcomes are 28-day and 90-day mortality, and ICU-free and IMV-free days in the first 28 days. RESULTS AND CONCLUSIONS: RENOVATE is designed to provide evidence on whether HFNC therapy improves, compared with NIPPV, important patient-centred outcomes in different aetiologies of ARF. Here, we describe the rationale, design and status of the trial. TRIAL REGISTRATION: ClinicalTrials.gov NCT03643939.
Objective
To describe the IMPACTO-MR, a Brazilian nationwide intensive care unit
platform study focused on the impact of health care-associated infections
due to multidrug-resistant bacteria.
Methods
We described the IMPACTO-MR platform, its development, criteria for intensive
care unit selection, characterization of core data collection, objectives,
and future research projects to be held within the platform.
Results
The core data were collected using the Epimed Monitor System® and
consisted of demographic data, comorbidity data, functional status, clinical
scores, admission diagnosis and secondary diagnoses, laboratory, clinical,
and microbiological data, and organ support during intensive care unit stay,
among others. From October 2019 to December 2020, 33,983 patients from 51
intensive care units were included in the core database.
Conclusion
The IMPACTO-MR platform is a nationwide Brazilian intensive care unit
clinical database focused on researching the impact of health
care-associated infections due to multidrug-resistant bacteria. This
platform provides data for individual intensive care unit development and
research and multicenter observational and prospective trials.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.